The Emerging Role of Admixture in the Pharmacogenetics of Puerto Rican Hispanics

Jorge Duconge* and Gualberto Ruaño

1University of Puerto Rico School of Pharmacy, Medical Sciences Campus, Pharmaceutical Sciences Department, San Juan PR 00936
2Genetic Research Center, Hartford Hospital, Hartford, CT 06106

Abstract

Admixture is of great relevance to the clinical application of pharmacogenetics and personalized medicine. Preliminary findings in Puerto Ricans further substantiate the argument for admixture as a critical covariate in a customized DNA-guided warfarin dosing algorithm. To this purpose, a genome-wide approach that incorporates admixture as an independent predictor of dose variability in DNA-guided algorithms has been postulated. Admixture is expected to be able to reveal some relevant associations in the genetic epidemiology of Hispanics and will be indispensable to assure that pharmacogenomic research can be pursued in such mixed populations. Consequently, the clinical utility of knowing an individual’s genotype before initiating drug treatment in Puerto Ricans, and Hispanics in general, will finally be untangled by developing a “Genetic Prescription Model” that takes admixture into consideration. This approach will help lead physicians and patients to their desired treatment goal, resulting in more effective healthcare in admixed people.

Keywords: Admixture; Personalized medicine; Puerto ricans; Pharmacogenetics; Warfarin

Introduction

A major advance in healthcare would be a transition from the current empirical approaches in drug therapy to a genetically predictive framework for determining the individual patient’s response to medicines. The richer mixture of genetic variants in admixed populations, including that observed in Puerto Ricans, is likely to contribute substantially to wider variability in response to drug therapies within these populations, a component that will be missed by traditional studies in more homogeneous populations. This addressable oversight is of great concern, since it will tend to exacerbate the healthcare disparity already experienced by Hispanic populations in the USA. Accordingly, an understanding of how human genetic diversity and admixture in Hispanics is structured is not only of anthropological importance, but also of medical relevance.

At the writing of this commentary, PubMed database lists only 20 entries, including letter to editors and reviews, for a query combining the terms “pharmacogenetics/genomics and admixture”. Lerman [1] argued that explanations for the lack of consistency in the results of genetic association studies for smoking cessation treatments include biases in ethnic admixture [1]. Corvol and co-workers of the GALA and genetic association studies for smoking cessation treatments include arguments that explanations for the lack of consistency in the results of the terms “pharmacogenetics/genomics and admixture”. Lerman [1] argued that explanations for the lack of consistency in the results of genetic association studies for smoking cessation treatments include biases in ethnic admixture [1]. Corvol and co-workers of the GALA and genetic association studies for smoking cessation treatments include arguments that explanations for the lack of consistency in the results of genetic association studies for smoking cessation treatments include biases in ethnic admixture [1].

Bryc et al. [7] found evidence of a significant sex bias in admixture proportions of Hispanics that is consistent with disproportionate contribution of European male and Amerindian or African female ancestry to present populations [7]. These authors also suggested that future genome-wide association studies in Hispanics will require correction for local genomic ancestry at a sub-continental scale [7].

Taken altogether, these still limited numbers of reports are suggesting that populations with varying levels of admixture can be particularly useful for pharmacogenetics/genomics and genetic-epidemiologic studies. For example, the self-reported degree of white admixture was found strongly correlated with protection from Hispanic response in Latinos (better in Mexican than Puerto Ricans, which is likely a consequence of a relatively higher contribution of Native American ancestry to Mexicans and, conversely, a relatively higher European proportions in Puerto Ricans).

Suarez-Kurtz and co-workers [3-5] have recently shown that the distribution of polymorphisms in various genes of pharmacological relevance, such as ABCB1, CYP3A5, GNB3, and GSTM1, among the population of Rio de Janeiro in Brazil, is best fit by a continuous function of the proportion of individual African ancestry, irrespective of self-reported race/color categories. It is reasonable to anticipate that the continuum in genetic ancestry within admixed populations like Hispanics will be reflected in the frequency distribution of pharmacogenetic polymorphisms. Perini et al. [6] observed that the required weekly dose of warfarin to achieve the target INR varied over tenfold within each race group in Brazilian patients [6].

*Corresponding author: Jorge Duconge, Department of Pharmaceutical Sciences Room 420, University of Puerto, Rico School of Pharmacy, Medical Sciences Campus PO Box 365067, San Juan, PR 00936-5067, Tel: (787) 758 2525 ext. 5410, 5418; Fax: (787) 767 2796; E-mail: jorge.duconge@upr.edu

Received September 09, 2010; Accepted October 04, 2010; Published October 04, 2010


Copyright: © 2010 Duconge J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
type 2 diabetes mellitus in the Pima Indian population [8]; differences in relative European ancestry proportions correlate with higher susceptibility in Puerto Ricans to asthma as compared with Mexicans [9]; and the increased risk of cardiovascular disease and hypertension in Puerto Ricans from Boston with greater African ancestry [10].

Backgrounds

Recently, the pharmacogenetic analysis of a significant physiogenomic (PG) data from Puerto Ricans has been accomplished to infer admixture structure and trichotomous ancestry in such a population by using an array of 384 SNPs (Single Nucleotide Polymorphisms) in 222 cardio-metabolic and neuro-endocrine candidate genes coding for key pharmaceutical targets. The genotypes and allele frequencies are publically available as an online supplement to the publication of this study [11].

The Puerto Rican population represents different admixtures of 3 major ethnographic groups (i.e., Amerindians, Europeans and West-Africans). Each subject in the study population was a ‘genetic mosaic’, with contributions from each of these three clusters, but in widely different proportions. Results also indicate that the admixture in the Puerto Rican population exists in the form of a continuous gradient with varying levels of admixture [11]. Such admixture results in a rich repertoire of combinatorial genotypes for key pharmacological, biochemical and physiological pathways, rendering Puerto Ricans a better resource to develop DNA-guided systems for clinical management of cardio-metabolic diseases (e.g., diabetes), urgent medical needs not only in Hispanic Puerto Ricans but also in the population at large. Accordingly, within the broad personalization paradigm, we have an enormous opportunity to turn our genetic variability into a clinical asset [12].

Figure 1 depicts the structure triangle derived from a Bayesian clustering analysis of a sample (n=100) representative of the Puerto Rican population, using the PG-array and the STRUCTURE v2.2 software package [13-14] in order to describe different levels of substructure in the data. This program takes genotype data from individuals without considering their origin and infers populations to which the individuals are assigned in such a way that linkage disequilibrium and Hardy-Weinberg disequilibrium are minimized within each inferred population. Each analyzed individual can belong to one or several inferred populations according to its “coefficients of ancestry”. This analysis is to determine how many ancestral groups contribute to the study population. However, it is important to mention that the assignment of the individuals in different inferred populations cannot be easily interpreted in terms of population history because STRUCTURE does not give any indication of the relevance of these units nor of their differentiation with regard to the other inferred populations.

Each individual was represented by a dot in the Figure 1. We performed a series of 3 Markov chain Monte Carlo simulation runs, ranging from K=1 to 5 with 80,000 iterations, as optimization algorithm for choosing a cluster size. Log-likelihood for each run was calculated as an a posteriori probability. Overall, results pointed toward a good fit for three clusters. Assuming K=3, proximity value (between 0 and 1) corresponding to each of 3 vertices of the triangle were calculated to each dot in the triangle. Closer proximity to any vertex resulted in proportionally higher value. We then assigned each individual to one of the three clusters by determining which of the three proximity values was greatest. A categorical criterion of proximity was added requiring that in order for an individual to be assigned to a specific cluster, its higher proximity value must be greater than the two others by at least 0.2. Thus excluding individuals not clearly positioned towards any vertex but rather located near the middle of the triangle. We added these dashed lines to separate the regions out each other. The degree of admixture in the study sample was evident as no one plotted dot was clearly placed on any of the three vertices of the structure triangle but rather positioned toward the borderline of the categorical criterion of proximity or the middle of the triangle. Some individuals overlapped in their position in the triangle.

In contrast to the results observed from a reference population of Kentucky (results not showed), most individuals in the Puerto Rican sample were found to be highly admixed between the three inferred populations (i.e., A thru C, Figure 1). 30 Caucasians from the Kentucky population showed a practically null admixture of the inferred populations A and C, whereas 10 African-Americans from Kentucky exhibited a more moderate admixture from the inferred populations A and B. It is worth noting that the assignments of individuals to inferred populations were not stable when the number of inferred populations is changed. That is, some individuals drastically changed their coefficients of ancestry between inferred populations when the number of inferred populations was increased from two to three. This is because we used a model in which the allele frequencies in the inferred populations at each locus are correlated with each other. The choice of this model is based on the assumption that all human populations originated from a single ancestral source population quite recently.

The majority of genetic analyses concerning population structure have assigned individuals into a small number of clusters, corresponding to four or five major racial/ethnic categories, but such classification is not completely discontinuous given the continuous intermixing among groups. In particular, genetic admixture has been well documented in different populations and, today, it is well accepted that admixture represent genetic gradations (geographic cline) [15]. In the Americas, the proportions of admixture will vary...
The first step in developing the genetic rules for personalized medicine is clinical research to “train the algorithms” supporting medical decision making [12]. Admixture introduces distinct levels of population sub-structure or stratum, with marked variations in individual ancestry among the members of a particular population or ethnic group, depending on the dynamics of the process. Accordingly, any extrapolations of clinically relevant pharmacogenetic data from non-admixed to admixed groups will be plagued with uncertainty as exemplified by Suarez-Kurtz [16]. The predictive power of previously published DNA-guided warfarin dosing algorithms for admixed populations like Puerto Ricans is inadequate. We have conducted an exploratory study to test association between combinatorial populations like Puerto Ricans is inadequate. We have conducted an exploratory study to test association between combinatorial polymorphisms on warfarin dose using the published algorithm by International Warfarin Pharmacogenetics Consortium (IWPC) [17]. The algorithm performed poorly when applied to our Puerto Rican patient cohort, with significant scatter, low correlation coefficient ($r^2=0.36$), high mean bias (25%), and high absolute difference (AD) values of 7.9 mg/week, respectively.

Recently, Villagra et al. [18] provided valuable evidence on the importance of controlling for admixture in pharmacogenetic studies of Puerto Rican Hispanics and stress the argument for incorporating admixture-matching in order to probe variations in warfarin response across different genotypes (i.e., stratification of the Puerto Rican population) [18]. Figure 2 depicts the increased prevalence of $VKORC1$-1639G>A allele in sector 1 of the dendrogram versus the rest of the population, which was consistent with previous assignment of sector 1 as primarily of Amerindian descent. The higher proportions of individuals carrying the $VKORC1$ haplotype A in sector 1 are requiring reduced warfarin doses in comparison to individuals assigned to the other two sectors, according to their respective ancestral coefficients. In this study we observed that inter-individual variations in ancestral contributions of Puerto Ricans will have significant implications for the way each individual responds to warfarin therapy [18]. Therefore, admixture may explain deviations from published algorithms. The results of admixture analysis can thus be utilized to parameterize population structure appropriately and account for it as a covariate in the corresponding association studies.

It is also important to recognize that some minority groups in the U.S. (e.g., Hispanics) might be highly underrepresented in typical clinical pharmacogenetic trials, such as those conducted to derive DNA-guided dosing algorithms for warfarin, relative to the real impact of these groups on the current U.S. population. Thus, most of the previously published models might not be optimal for validating a globally derived algorithm. Because of the heterogeneity and extensive admixture of the Puerto Rican population, extrapolation on a global scale of data derived from well-defined ethnic groups (i.e., Caucasians) is clearly not applicable to the majority of Puerto Ricans.

**Future Work**

Available data suggest that allele frequency of polymorphisms in genes of pharmacological relevance may differ significantly among populations. However, even larger intra-ethnic variability is also evident, particularly in admixed groups [16]. As pharmacogenomic-guided multi-gene models are developed to predict drug response, the range of possible allelic combinations in the Puerto Rican population is certain to exceed that in populations without such degree of admixture. When treating individual Puerto Ricans, the focus must be shifted from population to the inherent genetic individuality that result from unique mosaics of variable combinatorial genotypes.
a notion particularly important for admixed populations, in which stratification and substructure created by inter-ethnic gene flow further increases the fluidity of ethnic labels.

Due to a current lack of sufficient data in this admixed population, we believe that the clinical utility of knowing an individual's genotype before initiating warfarin treatment in Puerto Ricans is still an open question. On the other hand, known or cryptic population stratification created by admixture can have a strong confounding effect on genetic association analysis of clinical drug responses. It further substantiates the argument for including admixture as a critical covariate in future customized warfarin dosing algorithm. That is, rather than allocate the subject to a single stratum in the analysis, it is desirable to construct a new covariate for each stratum, giving the corresponding ancestral proportion derived from physiogenomic-driven STRUCTURE-based clustering analysis and then include these covariates as adjustment variables in multistep regression models to develop a DNA-guided algorithm for warfarin dosing.

Another potential use of admixture analysis in the context of pharmacogenomic studies is to gather valuable information on groups that are usually either excluded or underrepresented in clinical drug trials (i.e., Hispanics). Moreover, gene flow between two or more genetically distinct populations results in admixture linkage disequilibrium (ALD) stretches among all loci (linked and unlinked) that have different allele frequencies in the founding populations, in a longer proportion than isolated populations, which enable fewer markers to be used in genetic association studies [19].

Admixture analysis can also be used to reflect relevant environmental and socioeconomic differences in the Puerto Rican population across the island. Although usually classified as a single ethnic group by researchers, Hispanics are heterogeneous from cultural, socioeconomic, and genetic perspectives. We envisage that the admixture analysis will illustrate the unique opportunity Puerto Ricans offer for studying the interaction between racial, genetic, socioeconomic and environmental contributions to drug response. Strikingly, Choudhry et al. [20] using 44 AIMS found that among Puerto Ricans, ancestry was associated with socioeconomic status. That is, Puerto Ricans reporting “upper” socioeconomic status had 9.1% lower African ancestry and 9.2% higher European ancestry than individuals reporting “middle” and “middle” socioeconomic status [20]. In addition, correlations may be apparent with socioeconomic history, for example between African ancestry and location of sugar mills, plantations and slave ports. Using this admixture analysis, the history of migration and mixture in the Island of Puerto Rico can be reconstructed. Thus, future research among Puerto Rican and other Hispanic admixed populations should complement clinical genetic data with measures of ancestry, environmental and socioeconomic status.

A long-term goal is to extend the analysis of admixture in Puerto Ricans to genome wide (GW) arrays encompassing polymorphisms in all genes with 1.2 million SNP genotyping for fine resolution mapping of admixture. Admixture studies at this resolution afford delineation of candidate genes for pharmacogenetics not only for cardiovascular disease and diabetes, but also for other medical conditions of higher prevalence or incidence in Hispanics. The extremely high resolution of GW population analysis is able to resolve regional gradients in genetic dissimilarity. In a study of Europeans, it was possible to predict from GW genotype data the geographical point of origin of individuals to within a few hundred kilometers [21]. We will perform a similar analysis to examine whether there is a correlation between genetic and geographic distances, identify possible genetic gradients that will be useful in association studies and determine geographic stratification in the Island of Puerto Rico.

Conclusions

The population of the Americas carries a genomic legacy resulting from the European colonization and African slavery. In those parts of the Americas where admixture took hold, the populations manifest the combined anthropological heritage in their genomes, lifestyle, diet, and even socioeconomic status. Hispanics in the USA stand to gain the most from the revolution in personalized medicine, given longstanding disparities in healthcare afflicting them. At the same time, admixture analysis could become indispensable for the globalization of pharmacogenetic research beyond the Americas, to Africa, Asia and Europe, the continents whose populations contributed to the admixture in the first place.

Rather than ignoring admixture, pharmacogeneticists should consider it as starting point for better understanding the underlying basis of the observed wider variability in drug responses among patients of mixed populations. Such understanding provides the opportunity to develop strategies for leapfrogging the healthcare standards of these populations.

Acknowledgements

We acknowledge the support of National Institute of Health, National Center for Research Resources RCMI Award G12RR-03051; the Puerto Rican Newborn Screening Program and Genomas internal research and development funds.

References


14. The University of Chicago Department of Biological Sciences, Pritchard Lab. http://pritch.bsd.uchicago.edu


